Traumatic brain injury (TBI) is caused by a sudden external force disrupting normal brain function. Outcomes range from brief concussion to permanent cognitive and motor impairment. The secondary injury cascade — neuroinflammation, oxidative stress, blood-brain barrier disruption — continues for months after the initial trauma and is a major driver of long-term disability. MSC therapy targets this secondary injury phase.
Mechanisms in TBI
MSCs cross a disrupted blood-brain barrier and home to areas of injury. There they secrete neuroprotective factors, suppress glial scar formation, reduce microglial-driven inflammation, and promote angiogenesis. In controlled animal TBI models, MSC administration significantly reduces lesion volume, improves spatial memory performance, and accelerates motor recovery.
Clinical Evidence
Several Phase I/II trials have demonstrated safety and preliminary efficacy in moderate-to-severe TBI. Improvements in GCS scores, cognitive function testing, and functional independence measures (FIM) have been reported at 6–12 months post-treatment. Patients in the subacute phase (1–6 months post-injury) with ongoing deficits tend to show the strongest response.
Realistic Scope
MSC therapy after TBI can help optimize the recovery trajectory — it does not undo structural brain damage. Patients with chronic TBI (more than 2 years post-injury) may see more limited benefit as neuroplasticity windows narrow. Your physician will assess your injury chronology, current deficits, and imaging findings before recommending a protocol.